Kunst was ousted from the Seattle-based Aurion after Swiss eye-care giant Alcon acquired a majority interest in the company ...

UBS analyst Graham Doyle maintained a Buy rating on Alcon (ALC – Research Report) today and set a price target of CHF100.00. The company’s ...

Alcon acquired a majority interest in Aurion Biotech, a clinical-stage company developing advanced cell therapies to treat eye diseases. Terms of the deal weren't disclosed.

Alcon (ALC) announced the U.S. launch of SYSTANE PRO Preservative-Free PF as the latest over-the-counter eye drop in the company’s dry eye portfolio. SYSTANE PRO PF is the longest lasting eye ...

GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader ... as the latest over-the-counter eye drop in the company’s dry eye portfolio. SYSTANE PRO PF is the longest lasting eye ...

And in our experience, buying the right stocks can give your wealth a significant boost. To wit, the Alcon share price has climbed 78% in five years, easily topping the market return of 33% ...

the EX-PRESS ® Glaucoma Filtration Device and pharmaceutical drops. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years ...

Editor’s note: This is a developing news story. Please check back soon for updates. Alcon has acquired a majority interest in Aurion Biotech, according to a press release. Aurion will operate as ...

Please provide your email address to receive an email when new articles are posted on . Alcon will buy Lensar’s outstanding shares for $14 per share. The deal is expected to close in the second ...

Terms of the deal weren't disclosed. Aurion will operate as a separate company from Alcon, whose products include contact lenses and eye drops. The deal will also see Arnaud Lacoste, who most ...